Cargando…

Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome

CONTEXT: Wiedemann-Steiner Syndrome (WSS) is a genetic disorder associated with an array of clinical phenotypes, including advanced bone age and short stature. 11-ketotestosterone (11KT) is a member of the group known as 11-oxygenated C19 androgens that are implicated in premature adrenarche. CASE D...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchanan, Katherine, Greenup, Erin, Hurst, Anna C. E., Sunil, Bhuvana, Ashraf, Ambika P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574220/
https://www.ncbi.nlm.nih.gov/pubmed/36263329
http://dx.doi.org/10.3389/fendo.2022.1004114
_version_ 1784811060053671936
author Buchanan, Katherine
Greenup, Erin
Hurst, Anna C. E.
Sunil, Bhuvana
Ashraf, Ambika P.
author_facet Buchanan, Katherine
Greenup, Erin
Hurst, Anna C. E.
Sunil, Bhuvana
Ashraf, Ambika P.
author_sort Buchanan, Katherine
collection PubMed
description CONTEXT: Wiedemann-Steiner Syndrome (WSS) is a genetic disorder associated with an array of clinical phenotypes, including advanced bone age and short stature. 11-ketotestosterone (11KT) is a member of the group known as 11-oxygenated C19 androgens that are implicated in premature adrenarche. CASE DESCRIPTION: Case 1: The patient is a 3 year and 11-month-old female diagnosed with WSS due to deletion of KMT2A detected on CGH microarray. At two years and 11 months, imaging revealed an advanced bone age. We obtained an 11KT level on this patient. 11KT in case 1 was elevated at 26.3 ng/dL, while the normal reference range is 7.3-10.9 ng/dL and the reference interval for premature adrenarche is 12.3-22.9 ng/dL, The repeat 11KT at follow up (chronological age 4 years and 6 months) was still elevated at 33.8 ng/dL Case 2: A second child with WSS and a 5kb intragenic KMT2A deletion was evaluated at 11 months of age; his 11KT was 4.5 ng/dL. CONCLUSIONS: The elevated 11KT may indicate maturational changes related to increasing adrenal gland androgenic activation and may explain the advanced bone age seen in some patients with WSS. To our knowledge, this is the first case report that describes 11KT as a bioactive androgen potentially causing bone age advancement in WSS. Lack of elevation of 11KT in the second child who is an infant suggests increasing androgenic precursors and metabolites related to premature adrenarche may need to be longitudinally followed.
format Online
Article
Text
id pubmed-9574220
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95742202022-10-18 Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome Buchanan, Katherine Greenup, Erin Hurst, Anna C. E. Sunil, Bhuvana Ashraf, Ambika P. Front Endocrinol (Lausanne) Endocrinology CONTEXT: Wiedemann-Steiner Syndrome (WSS) is a genetic disorder associated with an array of clinical phenotypes, including advanced bone age and short stature. 11-ketotestosterone (11KT) is a member of the group known as 11-oxygenated C19 androgens that are implicated in premature adrenarche. CASE DESCRIPTION: Case 1: The patient is a 3 year and 11-month-old female diagnosed with WSS due to deletion of KMT2A detected on CGH microarray. At two years and 11 months, imaging revealed an advanced bone age. We obtained an 11KT level on this patient. 11KT in case 1 was elevated at 26.3 ng/dL, while the normal reference range is 7.3-10.9 ng/dL and the reference interval for premature adrenarche is 12.3-22.9 ng/dL, The repeat 11KT at follow up (chronological age 4 years and 6 months) was still elevated at 33.8 ng/dL Case 2: A second child with WSS and a 5kb intragenic KMT2A deletion was evaluated at 11 months of age; his 11KT was 4.5 ng/dL. CONCLUSIONS: The elevated 11KT may indicate maturational changes related to increasing adrenal gland androgenic activation and may explain the advanced bone age seen in some patients with WSS. To our knowledge, this is the first case report that describes 11KT as a bioactive androgen potentially causing bone age advancement in WSS. Lack of elevation of 11KT in the second child who is an infant suggests increasing androgenic precursors and metabolites related to premature adrenarche may need to be longitudinally followed. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9574220/ /pubmed/36263329 http://dx.doi.org/10.3389/fendo.2022.1004114 Text en Copyright © 2022 Buchanan, Greenup, Hurst, Sunil and Ashraf https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Buchanan, Katherine
Greenup, Erin
Hurst, Anna C. E.
Sunil, Bhuvana
Ashraf, Ambika P.
Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome
title Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome
title_full Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome
title_fullStr Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome
title_full_unstemmed Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome
title_short Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome
title_sort case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of wiedemann-steiner syndrome
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574220/
https://www.ncbi.nlm.nih.gov/pubmed/36263329
http://dx.doi.org/10.3389/fendo.2022.1004114
work_keys_str_mv AT buchanankatherine casereport11ketotestosteronemaypotentiateadvancedboneageasseeninsomecasesofwiedemannsteinersyndrome
AT greenuperin casereport11ketotestosteronemaypotentiateadvancedboneageasseeninsomecasesofwiedemannsteinersyndrome
AT hurstannace casereport11ketotestosteronemaypotentiateadvancedboneageasseeninsomecasesofwiedemannsteinersyndrome
AT sunilbhuvana casereport11ketotestosteronemaypotentiateadvancedboneageasseeninsomecasesofwiedemannsteinersyndrome
AT ashrafambikap casereport11ketotestosteronemaypotentiateadvancedboneageasseeninsomecasesofwiedemannsteinersyndrome